| Dr Steven Han, MD | |
|
515 Minor Ave, Suite 200, Seattle, WA 98104-2133 | |
| (206) 215-2580 | |
| (206) 215-2581 |
| Full Name | Dr Steven Han |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 25 Years |
| Location | 515 Minor Ave, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013033190 | NPI | - | NPPES |
| 1184865198 | Other | WA | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD00043687 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Issaquah | Issaquah, WA | Hospital |
| Swedish Medical Center | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pacmed Clinics | 2466350657 | 185 |
News Archive
Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
› Verified 8 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
› Verified 8 days ago
| Entity Name | Pacmed Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013061217 PECOS PAC ID: 2466350657 Enrollment ID: O20031226000033 |
News Archive
Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
› Verified 8 days ago
| Entity Name | Pacmed Clinics |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1437202249 PECOS PAC ID: 2466350657 Enrollment ID: O20040116000654 |
News Archive
Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Han, MD 805 Madison St, Suite 901, Seattle, WA 98104-1172 Ph: (206) 264-8100 | Dr Steven Han, MD 515 Minor Ave, Suite 200, Seattle, WA 98104-2133 Ph: (206) 215-2580 |
News Archive
Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
› Verified 8 days ago
Dr. Sandra Jane Hadjinian, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St., Seattle, WA 98195 Phone: 206-520-5000 | |
John Steele Mullen, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 515 Minor Ave, Suite 200, Seattle, WA 98104 Phone: 206-215-2580 Fax: 206-215-2581 | |
Jeffrey M Mccracken, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 747 Broadway, Seattle, WA 98122 Phone: 206-386-2043 Fax: 206-386-2508 | |
Dr. Carol Collins, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 272 Health Sciences, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-616-3294 | |
Dr. Daniel Warren Smith, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9709 3rd Ave Ne, Seattle, WA 98115 Phone: 206-860-4944 | |
Tristan Marriner Nicholson, MD, PHD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 |